Evaluation of the efficacy of duloxetine and venlafaxine in chemotherapy-induced neuropathy in cancer patients,A double-blind clinical trial with placebo

Phase 3

Recruiting

• Conditions: Drug-induced polyneuropathy.; Drug-induced polyneuropathy; G62.0

• Registration Number: IRCT20240314061286N1
• Lead Sponsor: Gorgan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 141

Inclusion Criteria

Age over 18 years and under 80 years
Cancer patients based on the diagnosis of the physician and the pathology sample
Willingness and consent to participate in the study
Do not use drugs that affect serotonin levels
Do not use painkillers and drugs effective on neuropathic pain routinely from two weeks before starting duloxetine or venlafaxine

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of the average BPI score in the group treated with duloxetine and venlafaxine and placebo. Timepoint: at the beginning of treatment, weeks 6 and 12. Method of measurement: brief pain inventory.;Comparison of mean SF36 score in the group treated with duloxetine and venlafaxine and placebo. Timepoint: at the beginning of treatment, weeks 6 and 12. Method of measurement: Item short form survey36.